Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EA-230 for reducing postoperative hospital stay after on-pump CABG
NL-OMON61091Phase 3Not yet recruiting
- Sponsor
- EBI
- Start
- Apr 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis comparing EA-230 with Placebo (2 arms). Primary endpoint: Required postoperative hospital length of stay. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
EA-230
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON61091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61091.